|Protocol #||Sponsor||Protocol Title|
|NCT02563002||Merck Sharp & Dohme Corp.|
|A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Since FDA approval in 2004, Avastin (bevacizumab), an anti-angiogenic antibody, has become a standard component of first-line chemotherapy treatment of metastatic colorectal cancer. It has been proven to improve survival when combined with several first-line chemotherapy regimens. Average survival for patients with metastatic colorectal cancer has more than doubled since 1998 with the introduction of bevacizumab and other new agents. Controversy exists, however, regarding the use anti-angiogenesis agents beyond disease progression.
NGOC oncologists provide patients with colorectal cancer a variety of treatment options for this disease, often working in collaboration with surgeons and interventional radiologists. .